AMS AMERICAN SHARED HOSPITAL SERVICES
Services-Medical Laboratories · NYSE · SEC CIK 744825 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY4.9%
TTM net income YoY-5.6%
TTM EPS YoY0.0%
Revenue 3-yr CAGR14.3%
Net income 3-yr CAGR—
Margins
Gross margin16.7%
Operating margin-13.0%
Net margin-7.7%
FCF margin22.4%
EBITDA margin4.2%
Returns
ROE-10.1%
ROA-4.2%
ROIC (approx.)-9.0%
Asset turnover0.55x
Leverage & solvency
Liabilities / assets52.7%
Debt / equity0.77x
Current ratio0.81x
Interest coverage-2.85x
Cash quality & payout
Operating cash flow / net income-2.15x
Accruals ratio-13.3%
Payout ratio—
Capex / revenue-5.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $28.08M | $28.34M |
| Cost of revenue | $23.02M | $19.16M |
| Gross profit | $5.06M | $9.19M |
| SG&A expense | $7.08M | $7.41M |
| Operating income | -$3.59M | -$2.81M |
| Interest expense | $1.57M | $1.50M |
| Pretax income | -$3.22M | $1.24M |
| Income tax | -$493,000 | -$295,000 |
| Net income | -$1.55M | $2.19M |
| EBITDA | $2.13M | $3.37M |
| EPS (basic) | -0.23 | 0.34 |
| EPS (diluted) | -0.23 | 0.33 |
| Weighted avg. shares (diluted) | 6.62M | 6.70M |
| Balance sheet | ||
| Cash & equivalents | $3.46M | $11.03M |
| Receivables | $10.52M | $11.61M |
| Current assets | $17.72M | $26.26M |
| PP&E, net | — | $72.85M |
| Goodwill | $1.26M | $1.26M |
| Intangibles | $78,000 | $78,000 |
| Total assets | $55.48M | $60.20M |
| Current liabilities | $23.44M | $10.40M |
| Short-term debt | $17.29M | $2.84M |
| Long-term debt | $0 | $17.34M |
| Total debt | $17.29M | $20.18M |
| Total liabilities | $27.79M | $30.17M |
| Shareholders' equity | $24.03M | $25.18M |
| Net debt | $13.83M | $9.16M |
| Shares outstanding | 6.58M | 6.42M |
| Cash flow statement | ||
| Operating cash flow | $3.10M | $167,000 |
| Capital expenditure | $7.63M | $7.94M |
| Free cash flow | -$4.54M | -$7.77M |
| Investing cash flow | -$7.63M | -$7.11M |
| Financing cash flow | -$3.03M | $4.41M |
| Depreciation & amortization | $5.71M | $6.17M |
| Stock-based compensation | $404,000 | $373,000 |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.